UCB (STU:UNC) Payments of Debt: €-641 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UNC UCB SA STU:UNC
90 GF Score
Price €242.90
GF Value €211.93
Valuation Modestly Overvalued
View Full Analysis

What is UCB Payments of Debt?

UCB STU:UNC +2.02% 90 Payments of Debt is €-641 Mil as of Dec. 2025. GuruFocus rates STU:UNC with a GF Score™ of 90/100 and a GF Value™ of €211.93 (Modestly Overvalued).

UCB's Payments of Debt for the six months ended in Dec. 2025 was €-619 Mil.

UCB's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was €-641 Mil.

UCB Payments of Debt Historical Data

* Premium members only.

The historical data trend for UCB's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Payments of Debt Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -716.00 -546.00 -424.00 -756.00 -641.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -326.00 -563.00 -193.00 -22.00 -619.00
STU:UNC
90GF Score
UCB SA STU:UNC
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-641 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-641 Mil mean?
UCB (STU:UNC) has a Payments of Debt of €-641 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on UCB and its competitors.
Is UCB's Payments of Debt too high?
UCB's current Payments of Debt is €-641 Mil. Overall, UCB has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Payments of Debt compare to VRTX and REGN?
UCB's Payments of Debt of €-641 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on UCB and its competitors. UCB's current Payments of Debt is €-641 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €211.93, compared to a current price of €242.90 — trading 14.6% above its estimated fair value. The current Payments of Debt is €-641 Mil. UCB's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For UCB (STU:UNC), the current Payments of Debt is €-641 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €242.90 is trading 14.6% above its estimated GF Value™ of €211.93. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Payments of Debt: €-641 Mil
  • GF Value™: €211.93 vs. price of €242.90 (14.6% above fair value)
  • GF Score™: 90/100

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score

Get the complete analysis for STU:UNC

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€242.90
Price
€211.93
GF Value